Harpoon Therapeutics, Inc.

NasdaqCM:HARP Voorraadrapport

Marktkapitalisatie: US$492.3m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Harpoon Therapeutics Beheer

Beheer criteriumcontroles 3/4

Harpoon Therapeutics' CEO is Julie Eastland, appointed in Nov 2021, has a tenure of 2.33 years. total yearly compensation is $1.16M, comprised of 48.7% salary and 51.3% bonuses, including company stock and options. directly owns 0.016% of the company’s shares, worth $80.60K. The average tenure of the management team and the board of directors is 1.4 years and 5.5 years respectively.

Belangrijke informatie

Julie Eastland

Algemeen directeur

US$1.2m

Totale compensatie

Percentage CEO-salaris48.7%
Dienstverband CEO2.3yrs
Eigendom CEO0.02%
Management gemiddelde ambtstermijn1.4yrs
Gemiddelde ambtstermijn bestuur5.5yrs

Recente managementupdates

Recent updates

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Jan 30
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Oct 01
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Aug 14
Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

May 28
Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Mar 11
Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Harpoon Therapeutics appoints Luke Walker as CMO

Oct 04

Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player

Sep 01

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Jul 30
Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio

Jul 07

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Mar 08
Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Nov 30
We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Harpoon Therapeutics: A First Look

Sep 16

Harpoon shares slide after early-stage prostate cancer study data fails to impress

Jun 04

Analyse CEO-vergoeding

Hoe is Julie Eastland's beloning veranderd ten opzichte van Harpoon Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2023n/an/a

-US$30m

Jun 30 2023n/an/a

-US$40m

Mar 31 2023n/an/a

-US$59m

Dec 31 2022US$1mUS$565k

-US$68m

Sep 30 2022n/an/a

-US$71m

Jun 30 2022n/an/a

-US$76m

Mar 31 2022n/an/a

-US$75m

Dec 31 2021US$2mUS$84k

-US$117m

Compensatie versus markt: Julie's total compensation ($USD1.16M) is below average for companies of similar size in the US market ($USD2.19M).

Compensatie versus inkomsten: Julie's compensation has been consistent with company performance over the past year.

CEO

Julie Eastland (59 yo)

2.3yrs

Tenure

US$1,160,774

Compensatie

Ms. Julie M. Eastland, M.B.A. served as Chief Operating Officer and Chief Financial Officer at Recode Therapeutics, Inc. since October 2020 until November 2021. She serves as the President and Chief Execut...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Julie Eastland
President2.3yrsUS$1.16m0.016%
$ 80.6k
Luke Walker
Chief Medical Officer1.4yrsUS$668.96k0%
$ 0
Michael Faerm
Interim Chief Financial Officerno datageen gegevensgeen gegevens
Chatan Charan
Senior Vice President of Product Development1.3yrsgeen gegevensgeen gegevens
James Bucher
Chief Legal Officerless than a yeargeen gegevensgeen gegevens
Wendy Chang
Chief People Officer1.7yrsgeen gegevensgeen gegevens
Banmeet Anand
Senior Vice President of Translational Medicine1.7yrsgeen gegevensgeen gegevens
Haibo Wang
Senior Vice President of Business Developmentless than a yeargeen gegevensgeen gegevens

1.4yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: HARP's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
Julie Eastland
President5.4yrsUS$1.16m0.016%
$ 80.6k
Ronald Hunt
Independent Director6.8yrsUS$59.56k0.036%
$ 179.5k
Joseph Bailes
Independent Director4yrsUS$58.56k0%
$ 0
Lauren Silvernail
Independent Director1.5yrsUS$37.76k0%
$ 0
Eric Small
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Jeffrey Ravetch
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Jonathan Drachman
Independent Director5.5yrsUS$58.56k0%
$ 0
Charles Rudin
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Scott Myers
Independent Chairman of the Board5.6yrsUS$109.62k0.083%
$ 406.5k
Andrew Robbins
Independent Director4yrsUS$62.06k0%
$ 0
Mark Chin
Independent Director6.8yrsUS$59.56k0.036%
$ 179.5k
Ramy Ibrahim
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens

5.5yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: HARP's board of directors are considered experienced (5.5 years average tenure).